# ClostraBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clostrabio

- Industry: Biotechnology
- Headquarters: Chicago, US
- Website: www.clostrabio.com
- Total disclosed funding: $9.9M
- Latest round: Series A (Sep 12, 2022)
- Investors on record: 1

## About

Based in Illinois, US, and founded in 2016, ClostraBio, Inc operates as a biotechnology research company that offers a platform that engages in developing a therapeutic drug. The company was Co-founded by Cathryn R. Nagler and Jeffrey A. Hubbell. In March 2025, ClostraBio, Inc. raised an undisclosed amount of venture funding from new investors Illinois Innovation Venture Fund and NextGen Nutrition Investment Partners. As of 2022, the company is led by its CEO Brett Newswanger. The company creates new therapeutics to treat inflammatory bowel disease (IBD) and food allergies. It focuses on the restoration of intestinal barrier-protective function and innate immunity that helps the firm directly treat diseases of the gut and food allergies. The biotechnology firm offers a platform that delivers solutions for research of bacterial metabolites targeting the gut-immune-brain axis. The company will use the March 2025 funding for further growth and development.

## Funding rounds

- Series A, Sep 12, 2022, $9.9M — Portal Innovations

## Investors

- Portal Innovations (https://capitalatlas.ai/funds/portal-innovations) — Series A